Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440)
1997

Resistance to the anti-cancer drug ilmofosine

publication Evidence: moderate

Author Information

Author(s): J Hofmann, I Utz, M Spitaler, S Hofer, M Rybczynska, WT Beck, DBJ Herrmann, H Grunicke

Primary Institution: Institute of Medical Chemistry and Biochemistry, University of Innsbruck

Hypothesis

The study investigates the resistance of different cell lines to the anti-cancer drug ilmofosine.

Conclusion

Multidrug-resistant cells are cross-resistant to ilmofosine, and the compound does not interact directly with P-glycoprotein.

Supporting Evidence

  • Multidrug-resistant cell lines showed cross-resistance to ilmofosine.
  • Ilmofosine does not enhance the activity of doxorubicin or vinblastine.
  • Dexniguldipine-HCl did not affect sensitivity to ilmofosine.
  • Long-term treatment with ilmofosine did not induce multidrug resistance.

Takeaway

Some cancer cells can resist a new drug called ilmofosine, making it less effective. This happens because the cells have changes that help them avoid the drug's effects.

Methodology

The study involved testing various cell lines for their resistance to ilmofosine and analyzing the expression of multidrug resistance genes.

Limitations

The study does not provide a comprehensive understanding of all mechanisms of resistance to ilmofosine.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication